Table 1.
Baseline Characteristics of the Study Population
| Variable | cTnT ≤15× ULN n=239 | cTnT >15× ULN n=338 | P Value |
|---|---|---|---|
| Demographics | |||
| Age, y | 82.4±5.1 | 82.4±5.8 | 0.99 |
| Female sex, n (%) | 135 (56) | 179 (53) | 0.44 |
| Body mass index, kg/m2 | 26.7±5.2 | 26.0±4.7 | 0.07 |
| Cardiac risk factors | |||
| Diabetes mellitus, n (%) | 67 (28) | 90 (27) | 0.70 |
| Hypercholesterolemia, n (%) | 143 (60) | 225 (67) | 0.11 |
| Hypertension, n (%) | 199 (83) | 289 (86) | 0.48 |
| Current smoker, n (%) | 17 (8) | 35 (11) | 0.23 |
| Coronary artery disease, n (%) | 140 (59) | 227 (67) | 0.036 |
| SYNTAX score | 15.5±11.0 | 17.0±13.2 | 0.28 |
| Multivessel disease, n (%) | 42 (18) | 85 (25) | 0.03 |
| Previous myocardial infarction, n (%) | 34 (14) | 53 (16) | 0.72 |
| Previous CABG, n (%) | 20 (9) | 27 (9) | 1.000 |
| Previous PCI, n (%) | 56 (23) | 91 (27) | 0.38 |
| Chronic obstructive pulmonary disease, n (%) | 35 (15) | 64 (19) | 0.18 |
| Renal dusfunction (GFR <60 mL/min per 1.73 m2) | 145 (61) | 250 (74) | 0.001 |
| Severity of aortic regurgitation, n (%) | 0.31 | ||
| None/mild | 215 (93) | 291 (91) | 0.35 |
| Moderate/severe | 16 (7) | 30 (9) | 0.35 |
| Severity mitral regurgitation, n (%) | 0.75 | ||
| None/mild | 181 (76) | 252 (75) | 0.77 |
| Moderate/severe | 58 (24) | 86 (25) | 0.77 |
| Left ventricular mass index, g/m2 | 149.1±46.0 | 142.0±41.9 | 0.11 |
| Atrial fibrillation, n (%) | 63/204 (31) | 76/268 (28) | 0.61 |
| NYHA III/IV, n (%) | 181 (76) | 223 (66) | 0.016 |
| CCS III/IV, n (%) | 32 (13) | 46 (14) | 1.000 |
| Logistic EuroScore (%) | 22.1±14.0 | 23.4±13.6 | 0.25 |
| STS score (%) | 6.1±3.6 | 7.6±5.9 | 0.001 |
| Post‐TAVI CK‐MB, μg/L | 5.3±2.5 | 17.8±40.3 | <0.001 |
CABG indicates coronary artery bypass graft; CCS, Canadian Cardiovascular Society; CK‐MB, creatine phosphokinase‐MB; cTnT, cardiac troponin T; GFR, glomerular filtration rate; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; ULN, upper limit of normal.